Clinical Trial Update: SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating SUPRAME-ACTengine IMA203 versus investigator's choice of treatment in previously treated, unresectable or metastatic cutaneous…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma

Drugs mentioned

• IMA203 (IMA203)

Snippet

Sponsor: Immatics US, Inc. | Conditions: Melanoma, Cutaneous Malignant | Phase 3 | Status: RECRUITING